---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040241"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:00:48.807836+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks

## Summary
- HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.
- Cash $152.5M at Dec 31, 2024; cash runway expected into 2026.
- Net loss $49.1M in Q4 2024 vs $88.1M in Q4 2023; full year 2024 net loss $266.8M.
- Enrolling GLEAM (SC291 autoimmune) and VIVID (SC262 B-cell cancers); data expected in 2025.
- Appointed Dhaval Patel as CSO and Tricia Stewart as CPO.

## SEC filing metadata
- accession: 0000950170-25-040241
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/0000950170-25-040241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/sana-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040241
- JSON: https://secwatch.observer/filing/0000950170-25-040241.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.